New prospects of mesenchymal stem cells for ameliorating temporal lobe epilepsy

Inflammopharmacology
Neveen A SalemShaimaa El-Shebiney

Abstract

Temporal lobe epilepsy (TLE) is present in 30% of epileptic patients and does not respond to conventional treatments. Bone marrow derived mesenchymal stem cells (BMSCs) induce endogenous neural stem cells, inhibit neurodegeneration, and promote brain self-repair mechanisms. The present study addresses the feasibility of BMSCs transplantation against pilocarpine-induced TLE experimentally. BMSCs were injected either intravenously (IV) or in hippocampus bilaterally (IC). Increased cell count of BMSCs was achieved via IC route. BMSCs treatment ameliorated the pilocarpine-induced neurochemical and histological changes, retained amino acid neurotransmitters to the normal level, downregulated the immunoreactivity to insulin growth factor-1 receptor, synaptophysin, and caspase-3 and reduced oxidative insult and inflammatory markers detected in epileptic model. It is worth noting that BMSCs IC-administered showed more pronounced effects than those administered via IV route. BMSCs transplantation presents a promise for TLE treatment that has to be elucidated clinically.

References

Oct 24, 2001·Epilepsy Research·S Arroyo, A de la Morena
Jan 17, 2002·Proceedings of the National Academy of Sciences of the United States of America·Leila Tarsa, Yukiko Goda
Jun 26, 2003·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Ja Wook KooYoo-Hun Suh
May 1, 1959·Archives of Biochemistry and Biophysics·G L ELLMAN
Oct 8, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Hideki KitauraSteven L Teitelbaum
Nov 3, 2004·Seizure : the Journal of the British Epilepsy Association·Heinz Gregor Wieser, Adrian Häne
Jan 25, 2005·Neurochemical Research·Qun WangAlbert Y Sun
Aug 24, 2005·Pharmacology, Biochemistry, and Behavior·Viviane S NascimentoMarta M F Fonteles
Oct 17, 2006·Drugs·Patrick Kwan, Martin J Brodie
Jun 15, 2007·Seizure : the Journal of the British Epilepsy Association·R RaedtP Boon
May 23, 2008·Brain, Behavior, and Immunity·Annamaria VezzaniTeresa Ravizza
Sep 2, 2009·Anais Da Academia Brasileira De Ciências·Fulvio A ScorzaEsper A Cavalheiro
Sep 24, 2009·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Miranda BrennemanSean I Savitz
Jan 19, 2010·Seizure : the Journal of the British Epilepsy Association·Zaquer S M Costa-FerroJaderson C DaCosta
Sep 7, 2011·Experimental Biology and Medicine·Emilia Amengual-CladeraIsabel Lladó
Dec 6, 2011·Biochemia Medica·Marija Grdic RajkovicKarmela Barisic
Aug 30, 2012·Nature Methods·Caroline A SchneiderKevin W Eliceiri
Oct 31, 2013·Clinical Neurology and Neurosurgery·Wyatt L RameyMartin E Weinand
Nov 2, 2013·The Journal of Clinical Investigation·Nolan R Williams, Michael S Okun
Feb 15, 2014·Free Radical Biology & Medicine·Michele Longoni CalióClélia Rejane Antônio Bertoncini
Sep 16, 2014·Neural Regeneration Research·Li XiaoRyoji Ide
Jun 3, 2015·Cold Spring Harbor Perspectives in Medicine·Carl E Stafstrom, Lionel Carmant

❮ Previous
Next ❯

Citations

Jun 5, 2020·Stem Cells Translational Medicine·Rhian Stavely, Kulmira Nurgali
Dec 24, 2020·International Journal of Molecular Sciences·Valentina SalariPaolo Francesco Fabene

❮ Previous
Next ❯

Methods Mentioned

BETA
Surgical resection
ELISA
flow cytometry

Software Mentioned

ImageJ
GraphPad
GraphPad Prism

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.